Prolia

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by subcutaneous injection
gptkbp:administered_every 6 months
gptkbp:approves gptkb:FDA
gptkbp:clinical_trial gptkb:ARCH_trial
gptkb:FREEDOM_trial
gptkb:REPLACE_trial
Phase 3
DATA trial
FREEDOM Extension trial
gptkbp:clinical_use treatment of osteoporosis
treatment of bone loss associated with hormone ablation
gptkbp:contraindication pregnancy
lactation
hypersensitivity to denosumab
hypocalcemia
gptkbp:dosage_form injection
gptkbp:excretion via the reticuloendothelial system
gptkbp:formulation solution for injection
https://www.w3.org/2000/01/rdf-schema#label Prolia
gptkbp:indication prevention of bone fractures
gptkbp:ingredients gptkb:denosumab
gptkbp:interacts_with other medications affecting calcium levels
gptkbp:is_monitored_by bone mineral density
calcium levels
gptkbp:lifespan about 26 days
gptkbp:long_term_use safety and efficacy established
gptkbp:manufacturer gptkb:Amgen
gptkbp:marketed_as gptkb:2010
gptkbp:mechanism_of_action RANKL inhibitor
gptkbp:packaging single-use prefilled syringe
gptkbp:patient_education importance of calcium and vitamin D
importance of regular dental check-ups
signs of infection to report
gptkbp:patient_population postmenopausal women
men at high risk for fracture
gptkbp:pharmacokinetics subcutaneous absorption
gptkbp:price varies by region and insurance
gptkbp:regulatory_compliance approved in multiple countries
gptkbp:requires available from manufacturer
gptkbp:route_of_administration subcutaneous
gptkbp:safety_features generally well tolerated
gptkbp:side_effect injection site reactions
skin rash
osteonecrosis of the jaw
hypocalcemia
atypical femoral fractures
gptkbp:storage refrigerated
gptkbp:trade gptkb:denosumab
gptkbp:used_for osteoporosis
gptkbp:bfsParent gptkb:Amgen
gptkbp:bfsLayer 4